HANGZHOU, China and SHANGHAI and BOSTON, Nov. 19, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development ...
Hosted on MSN
Summit Therapeutics outlines ivonescimab progress with key Phase III data expected mid-2025
Co-CEO Bob Duggan highlighted significant progress with ivonescimab, Summit Therapeutics' lead investigational asset, emphasizing its potential impact on unmet medical needs. Key milestones included ...
The public comment period on Trump's sweeping changes to student-loan repayment has ended, bringing borrowers a step closer to finalization.
Phase 3 ABTECT Trial evaluating obefazimod for moderately to severely active ulcerative colitis (“UC”) reaches 1,003 of 1,224 participants, representing 82% of target enrollment. Enrollment completion ...
In the Phase 2 MINDFuL trial of XPro™ in patients with early Alzheimer’s Disease (AD) with biomarkers of inflammation, the modified intent-to-treat (mITT) population (n=200) did not meet the primary ...
GRI Bio, Inc. has announced expected interim and topline data readouts from its Phase 2a biomarker study for the lead program GRI-0621, aimed at treating idiopathic pulmonary fibrosis (IPF), in Q2 and ...
PERTH AMBOY — The second phase of a massive three-phase project to rebuild NJ Transit's Raritan River Bridge began on a sweltering Tuesday, June 24. "So many of the coastal towns, of which I live in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results